Antidiabetic drug metformin is effective on the metabolism of asymmetric dimethylarginine in experimental liver injury

Diabetes Research and Clinical Practice

Volumn 106, Issue 2, 2014, Pages 295-302

  Bal, Fatih ^a   Bekpinar, Seldag ^a   Unlucerci, Yesim ^a   Kusku Kiraz, Zeynep ^a   Önder, Semen ^a   Uysal, Mujdat ^a   Gurdol, Figen ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Arginine; Asymmetric dimethylarginine; Dimethylarginine dimethylaminohydrolase; Inflammation; Liver injury; Metformin

Indexed keywords

ALANINE AMINOTRANSFERASE; ARGINASE; ARGININE; ASPARTATE AMINOTRANSFERASE; DIMETHYLARGININASE; GALACTOSAMINE; GLUTATHIONE; LIPOPOLYSACCHARIDE; METFORMIN; MYELOPEROXIDASE; N(G),N(G) DIMETHYLARGININE; AMIDASE; ANTIDIABETIC AGENT; N,N-DIMETHYLARGININE; PEROXIDASE; PROTECTIVE AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EXPERIMENTAL LIVER INJURY; HISTOPATHOLOGY; INFLAMMATION; MALE; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; ANALOGS AND DERIVATIVES; ANIMAL; DRUG-INDUCED LIVER INJURY; METABOLISM; PATHOLOGY;

ALANINE TRANSAMINASE; AMIDOHYDROLASES; ANIMALS; ARGININE; ASPARTATE AMINOTRANSFERASES; DRUG-INDUCED LIVER INJURY; GALACTOSAMINE; GLUTATHIONE; HYPOGLYCEMIC AGENTS; LIPOPOLYSACCHARIDES; MALE; METFORMIN; PEROXIDASE; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84920576009     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.08.028     Document Type: Article

References (49)

1. Yeni-Komshian H., Carantoni M., Abbasi F., Reaven G.M. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000, 23:171-175.
2. Can A., Bekpinar S., Gurdol F., Tutuncu Y., Unlucerci Y., Dinccag N. Dimethylarginines in patients with type 2 diabetes mellitus: Relation with the glycaemic control. Diabetes Res Clin Pract 2011, 94:e61-e64.
3. Altinova A.E., Arslan M., Sepici-Dincel A., Akturk M., Altan N., Toruner F.B. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab 2007, 92:1881-1885.
4. Nijveldt R.J., Teerlink T., Van Der Hoven B., Siroen M.P., Kuik D.J., Rauwerda J.A., et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003, 22:23-30.
5. Davis J.S., Darcy C.J., Yeo T.W., Jones C., McNeil Y.R., Stephens D.P., et al. Asymmetric dimethylarginine, endothelial nitric oxide bioavailability and mortality in sepsis. PLoS ONE 2011, 6:e17260.
6. Lluch P., Torondel B., Medina P., Segarra G., Del Olmo J.A., Serra M.A., et al. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol 2004, 41:55-59.
7. Lin K.Y., Ito A., Asagami T., Tsao P.S., Adimoolam S., Kimoto M., et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002, 106:987-992.
8. Xiong Y., Fu Y.F., Fu S.H., Zhou H.H. Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes. J Cardiovasc Pharmacol 2003, 42:191-196.
9. Lee J.H., Park G.H., Lee Y.K., Park J.H. Changes in the arginine methylation of organ proteins during the development of diabetes mellitus. Diabetes Res Clin Pract 2011, 94:111-118.
10. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002, 23:599-622.
11. Eid H.M., Lyberg T., Arnesen H., Seljeflot I. Insulin and adiponectin inhibit the TNFalpha-induced ADMA accumulation in human endothelial cells: the role of DDAH. Atherosclerosis 2007, 194:e1-e8.
12. Tiegs G., Wolter M., Wendel A. Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol 1989, 38:627-631.
13. Morikawa A., Kato Y., Sugiyama T., Koide N., Chakravortty D., Yoshida T., et al. Role of nitric oxide in lipopolysaccharide-induced hepatic injury in d-galactosamine-sensitized mice as an experimental endotoxic shock model. Infect Immun 1999, 67:1018-1024.
14. Liu J., Saavedra J.E., Lu T., Song J.G., Clark J., Waalkes M.P., et al. O(2)-Vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate protection against d-galactosamine/endotoxin-induced hepatotoxicity in mice: genomic analysis using microarrays. J Pharmacol Exp Ther 2002, 300:18-25.
15. Bailey C.J., Turner R.C. Metformin. N Engl J Med 1996, 334:574-579.
16. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
17. Zinman B., Harris S.B., Neuman J., Gerstein H.C., Retnakaran R.R., Raboud J., et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010, 376:103-111.
18. Tsoyi K., Jang H.J., Nizamutdinova I.T., Kim Y.M., Lee Y.S., Kim H.J., et al. Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol 2011, 162:1498-1508.
19. Łabuzek K., Liber S., Gabryel B., Okopień B. Metformin has adenosine-monophosphate activated protein kinase (AMPK)-independent effects on LPS-stimulated rat primary microglial cultures. Pharmacol Rep 2010, 62:827-848.
20. Asagami T., Abbasi F., Stuelinger M., Lamendola C., McLaughlin T., Cooke J.P., et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002, 51:843-846.
21. Alexander C., Rietschel E.T. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 2001, 7:167-202.
22. Miller S.I., Ernst R.K., Bader M.W.L.P.S. TLR4 and infectious disease diversity. Nat Rev Microbiol 2005, 3:36-46.
23. Munford R.S. Detoxifying endotoxin: time, place and person. J Endotoxin Res 2005, 11:69-84.
24. Xin H.Y., Jiang D.J., Jia S.J., Song K., Wang G.P., Li Y.J., et al. Regulation by DDAH/ADMA pathway of lipopolysaccharide-induced tissue factor expression in endothelial cells. Thromb Haemost 2007, 97:830-838.
25. Yuan H., Li L., Zheng W., Wan J., Ge P., Li H., et al. Antidiabetic drug metformin alleviates endotoxin-induced fulminant liver injury in mice. Int Immunopharmacol 2012, 12:682-688.
26. Krysiak R., Gdula-Dymek A., Okopień B. Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance. Pharmacol Rep 2013, 65:1311-1316.
27. Calixto M.C., Lintomen L., André D.M., Leiria L.O., Ferreira D., Lellis-Santos C., et al. Metformin attenuates the exacerbation of the allergic eosinophilic inflammation in high fat-diet-induced obesity in mice. PLoS One 2013, 8:e76786.
28. Corraliza I.M., Campo M.L., Soler G., Modolell M. Determination of arginase activity in macrophages: a micromethod. J Immunol Methods 1994, 174:231-235.
29. Teerlink T. Determination of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in biological samples by HPLC. Methods Mol Med 2005, 108:263-274.
30. Beutler E., Duron O., Kelly B.M. Improved method for the determination of blood glutathione. J Lab Clin Med 1963, 61:882-888.
31. Rachmilewitz D., Stamler J.S., Karmeli F., Mullins M.E., Singel D.J., Loscalzo J., et al. Peroxynitrite-induced rat colitis. A new model of colonic inflammation. Gastroenterology 1993, 105:1681-1688.
32. Tain Y.L., Baylis C. Determination of dimethylarginine dimethylaminohydrolase activity in the kidney. Kidney Int 2007, 72:886-889.
33. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985, 150:76-85.
34. Ochoa J.B., Bernard A.C., Mistry S.K., Morris S.M., Figert P.L., Maley M.E., et al. Trauma increases extrahepatic arginase activity. Surgery 2000, 127:419-426.
35. Längle F., Roth E., Steininger R., Winkler S., Mühlbacher F. Arginase release following liver reperfusion. Evidence of hemodynamic action of arginase infusions. Transplantation 1995, 59:1542-1549.
36. Nicholson B., Manner C.K., Kleeman J., MacLeod C.L. Sustained nitric oxide production in macrophages requires the arginine transporter CAT2. J Biol Chem 2001, 276:15881-15885.
37. Dhanakoti S.N., Brosnan J.T., Herzberg G.R., Brosnan M.E. Renal arginine synthesis: studies in vitro and in vivo. Am J Physiol 1990, 259:E437-E442.
38. Kielstein J.T., Veldink H., Martens-Lobenhoffer J., Haller H., Perthel R., Lovric S., et al. Unilateral nephrectomy causes an abrupt increase in inflammatory mediators and a simultaneous decrease in plasma ADMA: a study in living kidney donors. Am J Physiol Renal Physiol 2011, 301:F1042-F1046.
39. Zoccali C., Maas R., Cutrupi S., Pizzini P., Finocchiaro P., Cambareri F., et al. Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. Nephrol Dial Transplant 2007, 22:801-806.
40. Bekpinar S., Develi-Is S., Unlucerci Y., Kusku-Kiraz Z., Uysal M., Gurdol F. Modulation of arginine and asymmetric dimethylarginine concentrations in liver and plasma by exogenous hydrogen sulfide in LPS-induced endotoxemia. Can J Physiol Pharmacol 2013, 91:1071-1075.
41. Mashimo H., Goyal R.K. Lessons from genetically engineered animal models. IV. Nitric oxide synthase gene knockout mice. Am J Physiol 1999, 277:G745-G750.
42. Hierholzer C., Billiar T.R. Molecular mechanisms in the early phase of hemorrhagic shock. Langenbecks Arch Surg 2001, 386:302-308.
43. Davids M., Teerlink T. Plasma concentrations of arginine and asymmetric dimethylarginine do not reflect their intracellular concentrations in peripheral blood mononuclear cells. Metabolism 2013, 62:1455-1461.
44. Giriwono P.E., Shirakawa H., Hokazono H., Goto T., Komai M. Fermented barley extract supplementation maintained antioxidative defense suppressing lipopolysaccharide-induced inflammatory liver injury in rats. Biosci Biotechnol Biochem 2011, 75:1971-1976.
45. Peyssonnaux C., Cejudo-Martin P., Doedens A., Zinkernagel A.S., Johnson R.S., Nizet V. Cutting edge: essential role of hypoxia inducible factor-1 alpha in development of lipopolysaccharide-induced sepsis. J Immunol 2007, 178:7516-7519.
46. Heyman S.N., Rosen S., Rosenberger C. Hypoxia-inducible factors and the prevention of acute organ injury. Crit Care 2011, 15:209.
47. Yildirim A.O., Bulau P., Zakrzewicz D., Kitowska K.E., Weissmann N., Grimminger F., et al. Increased protein arginine methylation in chronic hypoxia: role of protein arginine methyltransferases. Am J Respir Cell Mol Biol 2006, 35:436-443.
48. Takiyama Y., Harumi T., Watanabe J., Fujita Y., Honjo J., Shimizu N., et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism. Diabetes 2011, 60:981-992. (see comment in PubMed Commons below).
49. Bestermann W.H. The ADMA-Metformin hypothesis: linking the cardiovascular consequences of the metabolic syndrome and type 2 diabetes. Cardiorenal Med 2011, 1:211-219.